Alert: We're here for you. Learn how COVID-19 may affect mesothelioma patients.


Fact Checked

Calretinin is a calcium-binding protein originally found in neurons. It is also overexpressed in most types of malignant mesothelioma. Pathologists use calretinin as a selective marker to diagnose mesothelioma, and researchers are testing the protein as a target for cancer therapy.

Jump to a Topic:

Pathologists use immunohistochemistryto tell apart different forms of cancer and different cancer cell types. Calretinin is one of several immunohistochemical markers used to diagnose malignant mesothelioma.

A 2017 study in BMC Cancer showed calretinin is useful for detecting all major subtypes of malignant mesothelioma except the sarcomatoid cell type. That study also discussed calretinin as a possible target for a new treatment approach.

A 2013 study in the International Journal of Cancer had already shown calretinin is essential for mesothelioma cell growth and survival.

What Is Calretinin?

Calretinin is a binding protein involved in calcium signaling. It is encoded by the CALB2 gene and plays an essential role in how cells work.

Calretinin is naturally expressed in certain neurons in the nervous system. It is also found in specialized cells such as Leydig cells, which produce testosterone in men.

The protein is expressed in several other locations, including hair follicles. Calretinin has become a useful biomarker for illnesses such as Hirschsprung disease and malignant mesothelioma.

Using Calretinin to Diagnose Mesothelioma

Calretinin is part of a group of antibodies used to identify malignant mesothelioma. Doctors use the protein to tell the difference between epithelioid and biphasic mesothelioma — the two most common cell types of the cancer. The protein also helps distinguish mesothelioma from adenocarcinoma.

Pathologists do this by staining a cancer tissue sample with a calretinin antibody that reacts to calretinin. A calretinin stain tests positive in most cases of mesothelioma.

Like many other biomarkers, calretinin is not useful for detecting sarcomatoid cells. Sarcomatoid mesothelioma is the rarest cell type and the most difficult to treat. Only about 31 percent of sarcomatoid cases test positive for calrentinin.

Pathologists may test for podoplanin, another immunohistochemical marker, when sarcomatoid mesothelioma is suspected.

In the 2017 BMC Cancer study, calretinin had a high success rate of detecting mesothelioma, except in sarcomatoid cases.

The study included 199 cases of pleural mesothelioma in Australia and Germany. It compared calretinin to mesothelin, an established biomarker found in all mesothelioma cells. Calretinin’s performance was comparable with mesothelin. Combining both markers increased diagnostic sensitivity from 66 to 75 percent.

Researchers hope combining calretinin and mesothelin with other biomarkers will one day make the early detection of malignant mesothelioma possible. Currently, most cases of mesothelioma are diagnosed after tumors spread and symptoms arise.

“That would be a major step toward the application of biomarkers in medical surveillance programs of workers with former exposure to asbestos,” the authors of the study concluded.

Differentiating Mesothelioma from Other Cancers

Calretinin was the first biomarker to differentiate epithelioid and biphasic mesothelioma from adenocarcinoma. Adenocarcinoma is the most common type of cancer that forms in the lungs, prostate, esophagus and colon.

There is a statistically significant difference in the staining pattern of calretinin between mesothelial cells and adenocarcinoma cells. Because of this, calretinin plays an important role in preventing mesothelioma misdiagnosis.

Calretinin as a Potential Target for Mesothelioma Treatment

In the 2013 study, researchers explored calretinin’s functions in tumor development. They found the depletion of calretinin in mice models led to mesothelioma cell death within 72 hours and blocked cell growth. These promising results make calretinin a potential target for mesothelioma gene therapy.

“These results demonstrate that downregulation of CR [calretinin] had a strong effect on the viability of MM [malignant mesothelioma] cells,” the authors of the study wrote.

A drug targeting CALB2 — the gene that encodes calretinin — could potentially treat mesothelioma. Another approach would be a drug that downregulates calretinin itself.

Get the Compensation You Deserve

File a Claim Mesothelioma Packet

Learn About Top Mesothelioma Treatments

Get Your Guide

Immunotherapy & Mesothelioma Clinical Trials

Find Treatment

Registered Nurse and Patient Advocate

Karen Selby joined in 2009. She is a registered nurse with a background in oncology and thoracic surgery and was the regional director of a tissue bank before becoming a Patient Advocate at The Mesothelioma Center. Karen has assisted surgeons with thoracic surgeries such as lung resections, lung transplants, pneumonectomies, pleurectomies and wedge resections. She is also a member of the Academy of Oncology Nurse & Patient Navigators.

Walter Pacheco, Managing Editor at
Edited by
Reviewed by placeholder
Medical Review By

4 Cited Article Sources

The sources on all content featured in The Mesothelioma Center at include medical and scientific studies, peer-reviewed studies and other research documents from reputable organizations.

  1. Johnen, G. et al. (2017, May 30). Calretinin as a blood-based biomarker for mesothelioma.
    Retrieved from:
  2. (2013, April 18). Calretinin is essential for mesothelioma cell growth/survival in vitro: A potential new target for malignant mesothelioma therapy?
    Retrieved from:
  3. Cancer Treatment Centers of America. (n.d.). Adenocarcinoma.
    Retrieved from:
  4. Chhieng, DC. et al. (2000, June 25). Calretinin staining pattern aids in the differentiation of mesothelioma from adenocarcinoma in serous effusions. Retrieved from:

Did this article help you?

Did this article help you?

Thank you for your feedback. Would you like to speak with a Patient Advocate?

Share this article

Last Modified March 6, 2020

Chat live with a patient advocate now